<DOC>
	<DOCNO>NCT02825979</DOCNO>
	<brief_summary>The EARLY-AF study center evaluation impact early invasive management Atrial Fibrillation . The primary goal study evaluate clinical effectiveness early invasive approach . Specifically , investigator aim evaluate PVI perform Arctic Front cryoballoon superior AAD first-line therapy prevent atrial arrhythmia recurrence ( arrhythmia relate symptom , hospitalisation , health care utilization ) .</brief_summary>
	<brief_title>Early Aggressive Invasive Intervention Atrial Fibrillation</brief_title>
	<detailed_description>The EARLY-AF study center evaluation impact early invasive management Atrial Fibrillation . All patient undergo loop recorder implantation ( REVEAL LINQ , Medtronic ) , also call insertable cardiac monitor ( ICM ) , time study enrolment use standard clinical implant procedure . The primary goal study evaluate clinical effectiveness early invasive approach . Specifically , investigator aim evaluate PVI perform Arctic Front cryoballoon superior AAD first-line therapy prevent atrial arrhythmia recurrence ( arrhythmia relate symptom , hospitalisation , health care utilization ) . The secondary goal program evaluate health relate quality life ( HRQOL ) impact associate early invasive intervention , comparison primary AAD therapy . This analysis center evaluation generic disease-specific HRQOL instrument order determine impact early invasive approach . A secondary benefit derivation Quality Adjusted Life Years ( QALYs ) score , use summary measure health outcome inform subsequent healthcare resource allocation decision .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Anti-Arrhythmia Agents</mesh_term>
	<mesh_term>Sotalol</mesh_term>
	<mesh_term>Flecainide</mesh_term>
	<mesh_term>Propafenone</mesh_term>
	<criteria>Nonpermanent AF document 12 lead ECG , Trans Telephonic Monitoring ( TTM ) Holter monitor within last 24 month Age 18 year old date consent Candidate ablation base AF symptomatic Informed Consent Regular ( daily ) use class 1 3 antiarrhythmic drug ( pillinthepocket AAD use permit ) sufficient therapeutic dos accord guideline ( flecainide &gt; 50 mg BID , sotalol &gt; 80 mg BID , propafenone &gt; 150 mg BID Previous leave atrial ( LA ) ablation LA surgery AF due reversible cause ( e.g . hyperthyroidism , cardiothoracic surgery ) Active Intracardiac Thrombus Preexisting pulmonary vein stenosis PV stent Preexisting hemidiaphragmatic paralysis Contraindication anticoagulation radiocontrast material Left atrial anteroposterior diameter great 5.5 cm transthoracic echocardiography Cardiac valve prosthesis Clinically significant ( moderatelysevere , severe ) mitral valve regurgitation stenosis Myocardial infarction , PCI / PTCA , coronary artery stenting 3month period precede consent date Cardiac surgery threemonth interval precede consent date Significant congenital heart defect ( include atrial septal defect PV abnormality include PFO ) NYHA class III IV congestive heart failure Left ventricular ejection fraction ( LVEF ) less 35 % Hypertrophic cardiomyopathy ( septal posterior wall thickness &gt; 1.5 cm ) Significant Chronic Kidney Disease ( CKD eGFR &lt; 30 ÂµMol/L ) Uncontrolled hyperthyroidism Cerebral ischemic event ( stroke TIAs ) sixmonth interval precede consent date Pregnancy Life expectancy le one ( 1 ) year Currently participate anticipate participate clinical trial drug , device biologic potential interfere result study Unwilling unable comply fully study procedure followup</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>